Epigenetic silencing therapy to enter first human trials, targeting CVD
Longevity.Technology
|
January 20, 2026
X min read
Longevity.Technology
|
January 20, 2026
Share on Social
More like this
News
Scribe’s cardiometabolic programs gain CIRM boost
June 19, 2026
BioWorld
Read Now
Press
Scribe’s cardiometabolic programs gain CIRM boost
June 19, 2026
BioWorld
Read Now
News
Scribe Therapeutics Awarded More Than $25 Million From CIRM to Accelerate Additional CRISPR-Based Gene Editing Therapies for Cardiometabolic Disease Into Clinical Trials
June 18, 2026
Read Now
Press
Scribe Therapeutics Awarded More Than $25 Million From CIRM to Accelerate Additional CRISPR-Based Gene Editing Therapies for Cardiometabolic Disease Into Clinical Trials
June 18, 2026
Read Now
News
Scribe Therapeutics Presents Late-Breaking Preclinical Data Supporting STX-1150, a Clinical-Stage Epigenetic Silencing Therapy Designed to Achieve Years of LDL-C Lowering After a Single Dose
May 28, 2026
Read Now
Press
Scribe Therapeutics Presents Late-Breaking Preclinical Data Supporting STX-1150, a Clinical-Stage Epigenetic Silencing Therapy Designed to Achieve Years of LDL-C Lowering After a Single Dose
May 28, 2026
Read Now
